MEDX Ventures Group

MEDX Xelerator is the firm's primary company-creation platform, operated as a medtech accelerator in partnership with Boston Scientific and Intellectual Ventures' Invention Science Fund. It identifies clinical needs, develops intellectual property, and builds operating companies around validated technologies. A $20 million investment from British group CBG in 2020 expanded the platform's capacity. The accelerator feeds companies into MEDX Ventures Group's portfolio for ongoing operational management.

Key strategic partners include Boston Scientific and Intellectual Ventures, both co-investors in the MEDX Xelerator platform. Sheba Medical Center serves as a clinical collaborator, providing real-world testing environments and physician-driven needs assessment. West Pharmaceutical Services joined as a strategic collaboration partner focused on early-stage innovation in drug delivery and device design.

MEDX uses a venture-creation model rather than traditional deal sourcing. The firm originates ideas internally or through its hospital and industry partnerships, files intellectual property, and then recruits a full operating management team to run each company. This means portfolio companies are typically controlled subsidiaries, not minority equity stakes.

The firm's primary model is company creation through its Xelerator accelerator, meaning it typically founds and operates companies rather than writing checks into third-party startups. MEDX's own materials and partnership structure emphasize building new entities around intellectual property it helps develop. Whether it makes opportunistic fund commitments or direct minority investments is not publicly disclosed.

MEDX Ventures Group is headquartered in Hingham, Massachusetts, but maintains offices in Or Yehuda and Sakhnin, Israel. The Israeli presence is central to its model: the firm draws on Israel's medtech talent pool and government-backed innovation incentives for R&D, while the US office handles regulatory strategy, US market access, and relationships with strategic partners like Boston Scientific.

MEDX focuses on the earliest stages—seed and startup—consistent with a company-creation model. Its strategy involves taking concepts through preclinical and early clinical validation. No public data suggests the firm operates later-stage growth equity or buyout funds.

MEDX is structured as an asset manager with a Generalist subtype, according to its own classification and public records. It is not a single-family or multi-family office. Harel Gadot founded the firm and serves as Chairman and CEO, but the underlying capital base is not linked to a single family's wealth and remains undisclosed.